Cover Image

市場進入的課題:腎細胞癌 (美國)

Market Access Impact (US) [RCC]

出版商 FirstWord 商品編碼 509314
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
市場進入的課題:腎細胞癌 (美國) Market Access Impact (US) [RCC]
出版日期: 2017年05月01日 內容資訊: 英文



  • Afinitor (Everolimus:Novartis)
  • Avastin (Bevacizumab:Roche)
  • Cabometyx (Cabozantinib:Exelixis)
  • Inlyta (Axitinib :Pfizer)
  • Lenvima (Lenvatinib:Eisai/Novartis)
  • Nexavar (Sorafenib:Bayer/Amgen)
  • Opdivo (Nivolumab:Bristol-Myers Squibb)
  • Sutent (Sunitinib:Pfizer)
  • Torisel (Temsirolimus:Pfizer)
  • Votrient (Pazopanib:Novartis)


  • 各種障礙對打入市場的影響
    • 醫生開出最多的品牌?
    • 市場障礙如何影響處方決定?
    • 哪些障礙影響最大?
  • 各品牌的障礙的影響
    • 有多少醫生開出你的品牌?有多少沒有但會考慮?
    • 為什麼醫生不開出你的品牌?他們以何種取代?
    • 互爭市佔率的競爭品牌為何?

Who wins when high costs drag the leading brand down?

Market barriers affect nearly a quarter of renal cell carcinoma (RCC) prescriptions in the US. High costs especially are preventing oncologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers are keeping doctors from prescribing your brand?

Get the answers in Market Access Impact: RCC (US) .

Based on a survey of 100 medical oncologists, the report covers 10 major therapies from Amgen, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Novartis, Pfizer, and Roche. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Top Takeaways

  • Cost is dragging the leading brand down: It sees the biggest barrier-related share loss-mainly because it's too expensive.
  • Some brands win when costs are high: The brand that sees the biggest net share gain owes nearly a third of it to other brands being too expensive.
  • Many doctors experience few barriers: 70 percent or more of surveyed doctors experience no more than one barrier with any of the surveyed brands.
  • Barriers affect nearly a quarter of prescriptions: Cost and market access barriers affect more prescriptions than all other barriers combined.
  • Hidden volatility: While the net effect is modest, many brands see significant share losses and gains. Win/loss breakdowns can help you spot-and exploit-competitors' weaknesses.
  • Doctors are open to alternatives: most are willing to consider brands they don't currently prescribe.

Insight into 10 Major RCC Drugs

  • Afinitor (everolimus; Novartis)
  • Avastin (bevacizumab; Roche)
  • Cabometyx (cabozantinib; Exelixis)
  • Inlyta (axitinib; Pfizer)
  • Lenvima (lenvatinib; Eisai/Novartis)
  • Nexavar (sorafenib; Bayer/Amgen)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Sutent (sunitinib; Pfizer)
  • Torisel (temsirolimus; Pfizer)
  • Votrient (pazopanib; Novartis)

Exploring Market Access Barriers

Market Access Impact: RCC (US) explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with RCC in total in the last month

We conducted the survey between April 3rd and 7th, 2017.

Back to Top